SCR 9168
Alternative Names: SCR-9168Latest Information Update: 27 Jun 2023
At a glance
- Originator Simcere Zaiming
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD47 antigen inhibitors; Macrophage stimulants; SIRPA protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 19 Apr 2023 Simcere Zaiming plans IND enabling studies for Haematological malignancies in China in the end of 2023
- 10 Apr 2023 Preclinical trials in Haematological malignancies in China (unspecified route) before April 2023
- 04 Apr 2023 Pharmacodynamics and adverse events data from preclinical studies were presented at the 114th Annual Meeting of the American Association for Cancer Research, 2023 (AACR-2023)